Evaxion Biotech A/S Stock Forecast, Price & News

+0.56 (+10.13 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $6.09
50-Day Range
MA: $6.93
52-Week Range
Now: $6.09
Volume260,737 shs
Average Volume116,980 shs
Market Capitalization$116.92 million
P/E RatioN/A
Dividend YieldN/A
Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:EVAX
Phone45 53 53 18 50
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$116.92 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

1.70 out of 5 stars

Medical Sector

248th out of 2,010 stocks

Biotechnology Industry

19th out of 143 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.56 (+10.13 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Evaxion Biotech A/S (NASDAQ:EVAX) Frequently Asked Questions

Is Evaxion Biotech A/S a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evaxion Biotech A/S in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Evaxion Biotech A/S stock.
View analyst ratings for Evaxion Biotech A/S
or view top-rated stocks.

What stocks does MarketBeat like better than Evaxion Biotech A/S?

Wall Street analysts have given Evaxion Biotech A/S a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Evaxion Biotech A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for EVAX?

2 equities research analysts have issued 1-year price targets for Evaxion Biotech A/S's shares. Their forecasts range from $18.00 to $18.00. On average, they anticipate Evaxion Biotech A/S's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 195.6% from the stock's current price.
View analysts' price targets for Evaxion Biotech A/S
or view top-rated stocks among Wall Street analysts.

Who are Evaxion Biotech A/S's key executives?

Evaxion Biotech A/S's management team includes the following people:
  • Dr. Lars Aage-Staal Wegner M.D., Chief Exec. Officer (Age 46, Pay $238k)
  • Dr. Niels Iversen Moeller M.D., Co-founder & Chief Bus. Officer (Age 42, Pay $175k)
  • Mr. Andreas Holm Mattsson, Co-Founder & Chief Innovation Officer (Age 45, Pay $175k)
  • Mr. Glenn S. Vraniak, Chief Financial Officer (Age 58, Pay $352k)
  • Dr. Jürgen Langhärig EMBA, Ph.D., Head of Bus. Devel.

Who are some of Evaxion Biotech A/S's key competitors?

When did Evaxion Biotech A/S IPO?

(EVAX) raised $31 million in an initial public offering on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. served as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

What is Evaxion Biotech A/S's stock symbol?

Evaxion Biotech A/S trades on the NASDAQ under the ticker symbol "EVAX."

When did Evaxion Biotech A/S's quiet period expire?

Evaxion Biotech A/S's quiet period expired on Wednesday, March 17th. Evaxion Biotech A/S had issued 3,000,000 shares in its initial public offering on February 5th. The total size of the offering was $30,000,000 based on an initial share price of $10.00. During Evaxion Biotech A/S's quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Evaxion Biotech A/S?

Shares of EVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evaxion Biotech A/S's stock price today?

One share of EVAX stock can currently be purchased for approximately $6.09.

How much money does Evaxion Biotech A/S make?

Evaxion Biotech A/S has a market capitalization of $116.92 million.

How many employees does Evaxion Biotech A/S have?

Evaxion Biotech A/S employs 36 workers across the globe.

What is Evaxion Biotech A/S's official website?

The official website for Evaxion Biotech A/S is

How can I contact Evaxion Biotech A/S?

The company can be reached via phone at 45 53 53 18 50.

This page was last updated on 4/10/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.